Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Financial burden in recipients of allogeneic hematopoietic cell transplantation.
Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, Noel P, Fauble V, Sproat L, Tilburt J, Leis JF, Mikhael J. Khera N, et al. Among authors: leis jf. Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81. doi: 10.1016/j.bbmt.2014.05.011. Epub 2014 May 24. Biol Blood Marrow Transplant. 2014. PMID: 24867778 Free article.
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B, Langston A, Pulsipher MA, McSweeney PA, Wade JC, Epner E, Bo Petersen F, Bethge WA, Maloney DG, Storb R. Kahl C, et al. Among authors: leis jf. Blood. 2007 Oct 1;110(7):2744-8. doi: 10.1182/blood-2007-03-078592. Epub 2007 Jun 26. Blood. 2007. PMID: 17595333 Free PMC article.
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Reeder CB, et al. Among authors: leis jf. Leukemia. 2009 Jul;23(7):1337-41. doi: 10.1038/leu.2009.26. Epub 2009 Feb 19. Leukemia. 2009. PMID: 19225538 Free PMC article. Clinical Trial.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. Porter DL, et al. Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503. doi: 10.1016/j.bbmt.2010.08.001. Epub 2010 Aug 10. Biol Blood Marrow Transplant. 2010. PMID: 20699125 Free PMC article.
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Cherington C, et al. Leuk Res. 2012 Sep;36(9):1147-51. doi: 10.1016/j.leukres.2012.04.021. Epub 2012 May 11. Leuk Res. 2012. PMID: 22578777
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Slack JL, et al. Among authors: leis jf. Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7. Biol Blood Marrow Transplant. 2013. PMID: 23664940 Free article.
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.
Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Sobecks RM, et al. Among authors: leis jf. Biol Blood Marrow Transplant. 2014 Sep;20(9):1390-8. doi: 10.1016/j.bbmt.2014.05.020. Epub 2014 May 28. Biol Blood Marrow Transplant. 2014. PMID: 24880021 Free PMC article.
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Reeder CB, et al. Among authors: leis jf. Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30. Br J Haematol. 2014. PMID: 24974945 Free article. Clinical Trial. No abstract available.
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. Brammer JE, et al. Among authors: leis jf. Biol Blood Marrow Transplant. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024. Epub 2014 Oct 16. Biol Blood Marrow Transplant. 2015. PMID: 25445641 Free article. Clinical Trial.
131 results